PharmGKB summary: very important pharmacogene information for CYP3A5LAMBA, Jatinder; HEBERT, Joan M; SCHUETZ, Erin G et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 7, pp 555-558, issn 1744-6872, 4 p.Article

Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and womenFLOYD, Michael D; GERVASINI, Guillermo; MASICA, Andrew L et al.Pharmacogenetics (London). 2003, Vol 13, Num 10, pp 595-606, issn 0960-314X, 12 p.Article

The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variabilityHUAN QIU; MATHÄS, Marianne; NESTLER, Sebastian et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 3, pp 167-178, issn 1744-6872, 12 p.Article

CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populationsBALRAM, C; QINGYU ZHOU; YIN BUN CHEUNG et al.European journal of clinical pharmacology. 2003, Vol 59, Num 2, pp 123-126, issn 0031-6970, 4 p.Article

Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptorUSUI, Tatsuhiro; SAITOH, Yukiya; KOMADA, Fusao et al.Biological & pharmaceutical bulletin. 2003, Vol 26, Num 4, pp 510-517, issn 0918-6158, 8 p.Article

CYP3A5 genotype is associated with elevated blood pressureFROMM, Martin F; SCHMIDT, Bernhard M. W; PAHL, Andreas et al.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 10, pp 737-741, issn 1744-6872, 5 p.Article

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantationGOTO, Maki; MASUDA, Satohiro; KIUCHI, Tetsuya et al.Pharmacogenetics (London). 2004, Vol 14, Num 7, pp 471-478, issn 0960-314X, 8 p.Article

Differential impact of the CYP3A5^*1 and CYP3A5^*3 alleles on pre-dose concentrations of two tacrolimus formulationsWEHLAND, Markus; BAUER, Steffen; BRAKEMEIER, Susanne et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 4, pp 179-184, issn 1744-6872, 6 p.Article

Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groupsLEE, Su-Jun; USMANI, Khawja A; CHANAS, Brian et al.Pharmacogenetics (London). 2003, Vol 13, Num 8, pp 461-472, issn 0960-314X, 12 p.Article

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish populationMIRGHANI, Rajaa A; SAYI, Jane; BERTILSSON, Leif et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 9, pp 637-645, issn 1744-6872, 9 p.Article

Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populationsSCHIRMER, Markus; TOLIAT, Mohammad R; HABERL, Michael et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 1, pp 59-71, issn 1744-6872, 13 p.Article

Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipientsUESUGI, Miwa; MASUDA, Satohiro; KATSURA, Toshiya et al.Pharmacogenetics and genomics (Print). 2006, Vol 16, Num 2, pp 119-127, issn 1744-6872, 9 p.Article

Lipid-lowering response to statins is affected by CYP3A5 polymorphismKIVISTÖ, Kari T; NIEMI, Mikko; SCHAEFFELER, Elke et al.Pharmacogenetics (London). 2004, Vol 14, Num 8, pp 523-525, issn 0960-314X, 3 p.Article

Phenotyping-genotyping of alternatively spliced genes in one step : study of CYP3A5*3 polymorphismBUSI, Florent; CRESTEIL, Thierry.Pharmacogenetics and genomics (Print). 2005, Vol 15, Num 6, pp 433-439, issn 1744-6872, 7 p.Article

Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressersTANG, Hui-Lin; XIE, Hong-Guang; YAO YAO et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 11, pp 713-720, issn 1744-6872, 8 p.Article

The effect of CYP3A5 6986A>G and ABCB 1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysisTERRAZZINO, Salvatore; QUAGLIA, Marco; STRATTA, Piero et al.Pharmacogenetics and genomics (Print). 2012, Vol 22, Num 8, pp 642-645, issn 1744-6872, 4 p.Article

CYP3A5^*1/^*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazoleCHANDEL, Nirupama; AGGARWAL, Pardeep K; MINZ, Mukut et al.Pharmacogenetics and genomics (Print). 2009, Vol 19, Num 6, pp 458-463, issn 1744-6872, 6 p.Article

Imidazopyridines as selective CYP3A4 inhibitorsXINYI SONG; XIAOHAI LI; RUIZ, Claudia H et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 4, pp 1611-1614, issn 0960-894X, 4 p.Article

4β-Hydroxycholesterol is a new endogenous CYP3A marker : relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and TanzaniansDICZFALUSY, Ulf; MIURA, Jun; AKLILLU, Eleni et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 3, pp 201-208, issn 1744-6872, 8 p.Article

Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphismsFANTA, Samuel; NIEMI, Mikko; JÖNSSON, Siv et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 2, pp 77-90, issn 1744-6872, 14 p.Article

1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantationELENS, Laure; CAPRON, Arnaud; VAN KERCKHOVE, Valérie et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 10, pp 873-883, issn 1744-6872, 11 p.Article

Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patientsFUKUDO, Masahide; YANO, Ikuko; UEMOTO, Shinji et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 5, pp 413-423, issn 1744-6872, 11 p.Article

In vitro metabolism of cyclosporine A by human kidney CYP3A5YANG DAI; IWANAGA, Kazunori; LIN, Yvonne S et al.Biochemical pharmacology. 2004, Vol 68, Num 9, pp 1889-1902, issn 0006-2952, 14 p.Article

Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West AfricaWOJNOWSKI, Leszek; TURNER, Paul C; PEDERSEN, Bonnie et al.Pharmacogenetics (London). 2004, Vol 14, Num 10, pp 691-700, issn 0960-314X, 10 p.Article

Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjectsKIM, Kyoung-Ah; PARK, Pil-Whan; PARK, Ji-Young et al.European journal of clinical pharmacology. 2008, Vol 64, Num 6, pp 589-597, issn 0031-6970, 9 p.Article